- Raw materials
- Antibacterials
- Tosatoxumab
Tosatoxumab API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Tosatoxumab | CAS No: 1374419-41-6 | GMP-certified suppliers
A medication that targets Staphylococcus aureus alpha-toxin to support treatment of healthcare-associated infections, including resistant MRSA and MSSA strains.
Product Snapshot
- Tosatoxumab is an investigational monoclonal antibody formulation
- It is primarily intended for oncology indications
- Regulatory approval is pending, with clinical trials ongoing in key markets including the US and Europe
Clinical Overview
The primary mechanism of action of tosatoxumab involves neutralization of the alpha-toxin, thereby preventing the toxin-mediated destruction of host immune cells. This protective effect supports host defense by mitigating damage caused by the toxin independently of bacterial antibiotic resistance mechanisms. By directly targeting the toxin rather than the bacteria, tosatoxumab aims to complement traditional antibiotic therapies and address infections caused by drug-resistant strains.
Pharmacodynamic data and specific clinical indications for tosatoxumab remain investigational and have not been formally established. Similarly, detailed pharmacokinetic and absorption, distribution, metabolism, and excretion (ADME) profiles are not publicly available. Safety and toxicity profiles have not been fully elucidated in published literature, reflecting the compound’s status as an investigational agent.
At present, tosatoxumab is not approved for clinical use and is under investigation for potential therapeutic applications in Staphylococcus aureus infections. No marketed brand names have been documented.
For sourcing and procurement, manufacturers and formulation scientists should ensure that tosatoxumab complies with stringent quality standards applicable to monoclonal antibody APIs. This includes confirmation of identity, purity, and biological activity through validated analytical methods. Given its biologic nature, cold chain logistics and handling procedures must be strictly observed to maintain product integrity. Regulatory documentation supporting clinical investigational use should be verified to ensure compliance with regional requirements.
Identification & chemistry
| Generic name | Tosatoxumab |
|---|---|
| Molecule type | Biotech |
| CAS | 1374419-41-6 |
| UNII | 6AA3OC17QR |
| DrugBank ID | DB16557 |
Pharmacology
| Summary | Tosatoxumab is a monoclonal antibody that targets Staphylococcus aureus alpha-toxin, a key virulence factor involved in MRSA and MSSA infections. By neutralizing alpha-toxin, it aims to mitigate tissue damage and pathogenic effects associated with S. aureus infections. Its mechanism is independent of bacterial antibiotic resistance profiles. |
|---|---|
| Mechanism of action | Staphylococcus aureus alpha-toxin is a virulence factor secreted by methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA), with S. aureus being a leading cause of hospital-acquired lower respiratory tract infections and bloodstream, skin, soft tissue, and surgical site infections. Tosatoxumab acts as a monoclonal antibody against infections caused by MRSA and MSSA by targeting the S. aureus alpha-toxin[A191829, L31568, L31573], with its mode of action being independent of the antibiotic resistance profile of S. aureus. |
Formulation & handling
- Tosatoxumab is a biotech investigational agent, likely requiring parenteral administration due to its biologic nature.
- Handling should consider cold chain storage to maintain stability and efficacy.
- Formulation development must address potential immunogenicity typical of biologic molecules.
Regulatory status
Tosatoxumab is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
